- Home
- PRQR vs IMMP Comparison
PRQR vs IMMP Comparison
Compare PRQR & IMMP Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- PRQR
- IMMP
- Stock Information
- Founded
- PRQR 2012
- IMMP 1987
- Country
- PRQR Netherlands
- IMMP Australia
- Employees
- PRQR N/A
- IMMP N/A
- Industry
- PRQR Biotechnology: Pharmaceutical Preparations
- IMMP Biotechnology: Pharmaceutical Preparations
- Sector
- PRQR Health Care
- IMMP Health Care
- Exchange
- PRQR Nasdaq
- IMMP Nasdaq
- Market Cap
- PRQR 309.5M
- IMMP 304.0M
- IPO Year
- PRQR 2014
- IMMP N/A
- Fundamental
- Price
- PRQR $1.69
- IMMP $1.81
- Analyst Decision
- PRQR Strong Buy
- IMMP Buy
- Analyst Count
- PRQR 6
- IMMP 2
- Target Price
- PRQR $8.50
- IMMP $8.50
- AVG Volume (30 Days)
- PRQR 414.8K
- IMMP 82.5K
- Earning Date
- PRQR 03-13-2025
- IMMP 03-25-2025
- Dividend Yield
- PRQR N/A
- IMMP N/A
- EPS Growth
- PRQR N/A
- IMMP N/A
- EPS
- PRQR N/A
- IMMP N/A
- Revenue
- PRQR $20,235,014.00
- IMMP $3,019,249.00
- Revenue This Year
- PRQR $39.44
- IMMP N/A
- Revenue Next Year
- PRQR N/A
- IMMP $20.28
- P/E Ratio
- PRQR N/A
- IMMP N/A
- Revenue Growth
- PRQR 196.41
- IMMP 24.11
- 52 Week Low
- PRQR $1.61
- IMMP $1.65
- 52 Week High
- PRQR $4.62
- IMMP $3.34
- Technical
- Relative Strength Index (RSI)
- PRQR 27.75
- IMMP 41.69
- Support Level
- PRQR $1.78
- IMMP $1.65
- Resistance Level
- PRQR $1.87
- IMMP $1.88
- Average True Range (ATR)
- PRQR 0.15
- IMMP 0.10
- MACD
- PRQR -0.05
- IMMP -0.01
- Stochastic Oscillator
- PRQR 0.00
- IMMP 41.94
About PRQR ProQR Therapeutics N.V.
ProQR Therapeutics NV is a biopharmaceuticals company. It discovers and develops RNA therapeutics for patients with severe genetic rare diseases such as cystic fibrosis, Leber's congenital amaurosis type 10 and dyastrophic epidermolysis bullosa.
About IMMP Immutep Limited
Immutep Ltd is a globally active biotechnology company developing immunotherapy products for cancer and autoimmune diseases. Its main product is IMP321, which involves clinical development for the treatment of cancer indications. The company is also focused on the development of other products, which include IMP701, which is a blocking anti-LAG-3 antibody for cancer and is in Phase I of its clinical trials, and CVac, which is a personalized immunocellular therapeutic investigated for the treatment of epithelial cancer. Geographically all the business activity of the firm is functioned through the region of Australia.